Pulmonx Corp Stock Investor Sentiment

LUNG Stock  USD 6.45  0.15  2.38%   
Roughly 60% of Pulmonx Corp's investor base is looking to short. The analysis of overall sentiment of trading Pulmonx Corp stock suggests that many investors are alarmed at this time. The current market sentiment, together with Pulmonx Corp's historical and current headlines, can help investors time the market. In addition, many technical investors use Pulmonx Corp stock news signals to limit their universe of possible portfolio assets.
  

Pulmonx Corp Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Pulmonx Corp can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over three weeks ago at finance.yahoo.com         
Pulmonx Third Quarter 2024 Earnings EPS Beats Expectations
Yahoo News
over three weeks ago at simplywall.st         
Pulmonx Third Quarter 2024 Earnings EPS Beats Expectations
Simply Wall St News at Macroaxis
over three weeks ago at insidermonkey.com         
Pulmonx Corporation Q3 2024 Earnings Call Transcript
insidermonkey News
over three weeks ago at finance.yahoo.com         
Geneial Secures Major Contract with RENCI and NHLBI to Partner with ARPA-H to Transform Biomedical D...
Yahoo News
over three weeks ago at gurufocus.com         
Pulmonx Corp Q3 2024 Earnings Call Highlights Strong Revenue Growth Amidst Strategic ...
Gurufocus Stories at Macroaxis
over three weeks ago at zacks.com         
Pulmonx Corporation Reports Q3 Loss, Misses Revenue Estimates
zacks News
over three weeks ago at gurufocus.com         
Pulmonx Corp Q3 2024 Earnings Revenue Hits 20.4M, EPS at -0.36, Surpassing Estimates
Gurufocus Stories at Macroaxis
over a month ago at simplywall.st         
Not Many Are Piling Into Pulmonx Corporation Stock Yet As It Plummets 27
Simply Wall St News at Macroaxis
over a month ago at investing.com         
Pulmonx director sells 130,399 in common stock
Investing News at Macroaxis
over a month ago at finance.yahoo.com         
The Lundquist Institute and Mayo Clinic Awarded 2.46M NIH Grant to Investigate Cellular Senescence i...
Yahoo News
over a month ago at www.macroaxis.com         
Disposition of 20000 shares by Glendon French of Pulmonx Corp at 6.52 subject to Rule 16b-3
Macroaxis News
over a month ago at finance.yahoo.com         
Pulmonx to Report Third Quarter 2024 Financial Results on October 30, 2024
Yahoo News
over a month ago at www.macroaxis.com         
Disposition of 20000 shares by Glendon French of Pulmonx Corp at 8.09 subject to Rule 16b-3
Macroaxis News
over a month ago at www.macroaxis.com         
Disposition of 20000 shares by Glendon French of Pulmonx Corp at 8.09 subject to Rule 16b-3
Macroaxis News
over a month ago at simplywall.st         
Is Pulmonx Using Debt In A Risky Way?
Simply Wall St News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Pulmonx Corp that are available to investors today. That information is available publicly through Pulmonx media outlets and privately through word of mouth or via Pulmonx internal channels. However, regardless of the origin, that massive amount of Pulmonx data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Pulmonx Corp news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Pulmonx Corp relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Pulmonx Corp's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Pulmonx Corp alpha.

Pulmonx Corp Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Acquisition by Geoffrey Rose of 34500 shares of Pulmonx Corp subject to Rule 16b-3
09/06/2024
2
Disposition of 20000 shares by Glendon French of Pulmonx Corp at 8.09 subject to Rule 16b-3
09/12/2024
3
Disposition of 20000 shares by Glendon French of Pulmonx Corp at 6.52 subject to Rule 16b-3
10/17/2024
4
Pulmonx director sells 130,399 in common stock
10/21/2024
5
Pulmonx Corp Q3 2024 Earnings Revenue Hits 20.4M, EPS at -0.36, Surpassing Estimates
10/30/2024
6
Geneial Secures Major Contract with RENCI and NHLBI to Partner with ARPA-H to Transform Biomedical Data Standardization with Advanced AI
10/31/2024
7
Pulmonx Corporation Q3 2024 Earnings Call Transcript
11/01/2024
8
TLI Investigators William Stringer MD and Asghar Abbasi PhD, along with Ke Zhang MD of Allerdia Inc., receive 2 Million NIHNHLBI Grant to Develop Novel Point-of...
11/06/2024
9
FMR LLC Bolsters Stake in Pulmonx Corp - GuruFocus.com
11/12/2024
10
Pulmonx to Present at the Piper Sandler 36th Annual Healthcare Conference
11/20/2024
11
Insider Selling Pulmonx Co. Director Sells 20,000 Shares of Stock
11/27/2024

Complementary Tools for Pulmonx Stock analysis

When running Pulmonx Corp's price analysis, check to measure Pulmonx Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pulmonx Corp is operating at the current time. Most of Pulmonx Corp's value examination focuses on studying past and present price action to predict the probability of Pulmonx Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pulmonx Corp's price. Additionally, you may evaluate how the addition of Pulmonx Corp to your portfolios can decrease your overall portfolio volatility.
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Commodity Directory
Find actively traded commodities issued by global exchanges
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance